Budget impact analysis of orphan drugs in Belgium: Estimates from 2008 to 2013

Journal of Medical Economics

Volumn 13, Issue 2, 2010, Pages 295-301

  Denis, Alain ^a   Mergaert, Lut ^a   Fostier, Christel ^a   Cleemput, Irina ^b   Simoens, Steven ^c  

^a Yellow Window Management Consultants   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Belgium; Budget impact; Orphan drugs; Price; Rare diseases; Reimbursement

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ARSENIC TRIOXIDE; BOSENTAN; BUSULFAN; CARBIDOPA PLUS LEVODOPA; CARGLUMIC ACID; CLOFARABINE; DASATINIB; DEFERASIROX; GALSULFASE; IDURONATE 2 SULFATASE; IMATINIB; LARONIDASE; LENALIDOMIDE; MITOTANE; NELARABINE; NILOTINIB; NITISINONE; ORPHAN DRUG; PEGVISOMANT; RAZOXANE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT SOMATOMEDIN C; SILDENAFIL; SITAXSENTAN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ARTICLE; BELGIUM; BUDGET; BUDGET IMPACT ANALYSIS; CALCULATION; CHRONIC MYELOID LEUKEMIA; DRUG COST; EUROPEAN UNION; FABRY DISEASE; GASTROINTESTINAL STROMAL TUMOR; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HEREDITARY TYROSINEMIA TYPE 1; HORMONE RESISTANCE; HOSPITAL; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INJECTION SITE EXTRAVASATION; IRON OVERLOAD; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MAROTEAUX LAMY SYNDROME; MULTIPLE MYELOMA; NAGS DEFICIENCY; PARKINSON DISEASE; PRIMARY GROWTH HORMONE INSENSITIVITY SYNDROME; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REGISTRATION; REIMBURSEMENT; TYROSINEMIA;

BELGIUM; BUDGETS; DRUG COSTS; HUMANS; ORPHAN DRUG PRODUCTION; POLICY; STATE MEDICINE;

EID: 77953354292     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.491427     Document Type: Article

References (13)

1. European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000;L 18/1.
2. European Medicines Agency. Annual Report of the European Medicines Agency 2007. London: European Medicines Agency, 2008.
3. Denis A, Simoens S, Fostier C, et al. Health technology assessment policy governing orphan diseases and orphan medicines. Brussels: Belgian Health Care Knowledge Centre, 2009.
4. Rinaldi A. Adopting an orphan. EMBO Rep 2005;6:507-510.
5. Heemstra HE, de Vrueh RL, van Weely S, et al. Orphan drug development across Europe: bottlenecks and opportunities. Drug Discov Today 2008;13:670-676.
6. Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 2009;25:1285-1293.
7. Cleemput I, Neyt M, Thiry N, et al. Cost-effectiveness thresholds in health care. Brussels: Belgian Healthcare Knowledge Centre, 2008.
8. Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology. Can J Clin Pharmacol 2009;16:e273-281.
9. McCabe C, Tsuchiya A, Claxton K, et al. Orphan drugs revisited. Q J Med 2006;99:341-345.
10. RIZIV. Pharmaceutical specialties. Brussels: RIZIV, 2010.
11. RIZIV. Monitoring of Reimbursement Significant Expenses (MORSE). Brussels: RIZIV, 2008.
12. Committee for Orphan Medicinal Products. January 2009 plenary meeting: monthly report. London: European Medicines Agency, 2009.
13. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008;26:551-556